Compare Aventis Pharma with Orchid Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs ORCHID PHARMA LTD - Comparison Results

SANOFI INDIA     Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA ORCHID PHARMA LTD SANOFI INDIA/
ORCHID PHARMA LTD
 
P/E (TTM) x 35.1 -0.5 - View Chart
P/BV x 6.2 0.1 5,222.1% View Chart
Dividend Yield % 1.4 0.0 -  

Financials

 SANOFI INDIA   ORCHID PHARMA LTD
EQUITY SHARE DATA
    SANOFI INDIA
Dec-18
ORCHID PHARMA LTD
Sep-13
SANOFI INDIA/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs6,840194 3,525.8%   
Low Rs4,63035 13,228.6%   
Sales per share (Unadj.) Rs1,203.1276.5 435.2%  
Earnings per share (Unadj.) Rs165.3-79.2 -208.6%  
Cash flow per share (Unadj.) Rs209.9-43.5 -483.0%  
Dividends per share (Unadj.) Rs84.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs963.653.9 1,786.5%  
Shares outstanding (eoy) m23.0370.45 32.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.80.4 1,151.0%   
Avg P/E ratio x34.7-1.4 -2,400.7%  
P/CF ratio (eoy) x27.3-2.6 -1,037.1%  
Price / Book Value ratio x6.02.1 280.4%  
Dividend payout %50.80-   
Avg Mkt Cap Rs m132,0788,067 1,637.4%   
No. of employees `0003.32.8 117.9%   
Total wages/salary Rs m4,0682,527 161.0%   
Avg. sales/employee Rs Th8,393.86,956.1 120.7%   
Avg. wages/employee Rs Th1,232.4902.5 136.5%   
Avg. net profit/employee Rs Th1,153.0-1,993.0 -57.9%   
INCOME DATA
Net Sales Rs m27,70819,477 142.3%  
Other income Rs m897407 220.3%   
Total revenues Rs m28,60519,884 143.9%   
Gross profit Rs m6,2351,103 565.5%  
Depreciation Rs m1,0272,519 40.8%   
Interest Rs m75,227 0.1%   
Profit before tax Rs m6,098-6,236 -97.8%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m2,292-125 -1,830.7%   
Profit after tax Rs m3,806-5,580 -68.2%  
Gross profit margin %22.55.7 397.5%  
Effective tax rate %37.62.0 1,872.2%   
Net profit margin %13.7-28.7 -47.9%  
BALANCE SHEET DATA
Current assets Rs m15,92211,014 144.6%   
Current liabilities Rs m6,23532,060 19.4%   
Net working cap to sales %35.0-108.1 -32.4%  
Current ratio x2.60.3 743.3%  
Inventory Days Days6495 67.1%  
Debtors Days Days2134 62.2%  
Net fixed assets Rs m7,53929,440 25.6%   
Share capital Rs m230705 32.6%   
"Free" reserves Rs m21,9622,043 1,075.2%   
Net worth Rs m22,1923,800 584.0%   
Long term debt Rs m09,018 0.0%   
Total assets Rs m29,83946,510 64.2%  
Interest coverage x872.1-0.2 -451,606.5%   
Debt to equity ratio x02.4 0.0%  
Sales to assets ratio x0.90.4 221.7%   
Return on assets %12.8-0.8 -1,681.3%  
Return on equity %17.2-146.9 -11.7%  
Return on capital %27.5-3.7 -736.6%  
Exports to sales %037.9 0.0%   
Imports to sales %022.6 0.0%   
Exports (fob) Rs mNA7,378 0.0%   
Imports (cif) Rs mNA4,406 0.0%   
Fx inflow Rs m7,5877,513 101.0%   
Fx outflow Rs m7,1455,649 126.5%   
Net fx Rs m4421,865 23.7%   
CASH FLOW
From Operations Rs m3,7391,682 222.3%  
From Investments Rs m-731-9,860 7.4%  
From Financial Activity Rs m-1,9726,644 -29.7%  
Net Cashflow Rs m1,036-1,535 -67.5%  

Share Holding

Indian Promoters % 0.0 32.3 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 4.6 313.0%  
FIIs % 14.6 3.3 442.4%  
ADR/GDR % 0.0 4.6 -  
Free float % 10.5 55.3 19.0%  
Shareholders   15,184 84,811 17.9%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   ALKEM LABORATORIES  PLETHICO PHARMA  WOCKHARDT  TORRENT PHARMA  FRESENIUS KABI ONCO.  

Compare SANOFI INDIA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Strengthening Rupee, Inflation & Factory Output Data, and Top Stocks in Action Today(Pre-Open)

On Friday, Indian share markets witnessed most of the buying interest during closing hours and ended on a strong note.

Related Views on News

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA 2017-18 Annual Report Analysis (Annual Result Update)

Apr 16, 2019 | Updated on Apr 16, 2019

Here's an analysis of the annual report of SANOFI INDIA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.

SANOFI INDIA Announces Quarterly Results (3QFY19); Net Profit Up 4.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, SANOFI INDIA has posted a net profit of Rs 793 m (up 4.3% YoY). Sales on the other hand came in at Rs 7 bn (up 8.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Sep 13, 2019 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - ORCHID PHARMA LTD COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS